WHO Virtual Scientific Consultation on the use of Live-attenuated Influenza Vaccines (LAIV) Against the H1N1 Pandemic Virus
In light of the widespread outbreak of the novel influenza A (H1N1) virus, there is a need to immunize large population groups. Global supply of pandemic vaccine is limited. Live attenuated influenza vaccines (LAIV) can expand the global supply of vaccines given that yields can be significantly higher with LAIV, compared to inactivated influenza vaccines (IIV). In order to make informed decisions regarding the use of LAIV in pandemic control, the WHO held an international virtual consultation on vaccine efficacy, vaccine delivery and potential safety issues that will facilitate planning and clinical trial design. There are several approaches to LAIV under development; however this consultation discussed only those that are currently licensed. The purpose of this meeting was three-fold:
- 1 To review the immunogenicity and effectiveness of LAIV, as well as potential safety concerns associated with using LAIV, in the current H1N1 pandemic.
- 2 To discuss experience with, and options for, alternate delivery devices for LAIV.
- 3 To discuss other relevant topics that may be useful in considering LAIV in the current H1N1 outbreak.